FDA Issues Information on Risk for Metabolic Acidosis
Zonisamide Linked to Metabolic Acidosis
Younger Patients Affected More Severely and More FrequentlyFollowing a review of updated clinical data, The Food and Drug Administration issued information today on the risk for metabolic acidosis in some patients taking the anti-convulsant agent zonisamide (Zonegran).
Zonisamide is indicated as adjunctive therapy in the treatment of partial seizures in adults with epilepsy. Metabolic acidosis is a disturbance in the body's acid-base balance that results in excessive acidity of the blood.
Metabolic acidosis can result in hyperventilation, and non-specific symptoms such as fatigue and anorexia, or more severe symptoms including cardiac arrhythmias or stupor. Chronic metabolic acidosis can have adverse effects on the kidneys and on bones, and can retard growth in children. Patients with predisposing conditions or therapies, including renal disease, severe respiratory disorders, diarrhea, surgery, ketogenic diet, or certain other drugs may be at greater risk for developing metabolic acidosis following treatment with zonisamide. The risk of zonisamide-induced metabolic acidosis appears to be more frequent and severe in younger patients.
FEB-23-09: Zonisamide Linked to Metabolic Acidosis [FDA: ZONISAMIDE CAUSING METABOLIC ACIDOSIS]
Legal HelpIf you or a loved one has suffered ill health as a result of using this drug, please click the link below and your complaint will be sent to a lawyer who may evaluate your claim at no cost or obligation.
Class Action Law Suits
Newsworthy Law Suits
Defective Products Lawsuits
Drug & Medical Claims Lawsuits
Food & Dietary Supplement Lawsuits
Personal Injury Lawsuits
Real Estate Lawsuits
Investment Fraud Lawsuits